Allogene Therapeutics presents dual CAR-T cell data for high-risk myeloma after BCMA therapy

Allogene Therapeutics presents dual CAR-T cell data for high-risk myeloma after BCMA therapy
Allogene CAR-T data at AACR26

Allogene Therapeutics is presenting new data on its allogeneic BCMA/CD70 dual CAR-T cells for patients with high-risk multiple myeloma who have previously received BCMA therapy.

The company outlined the potential of its off-the-shelf cell therapy approach at the AACR26 conference, emphasizing advancements designed to address unmet needs in the treatment of relapsed or refractory multiple myeloma. Allogene Therapeutics aims to expand options for patients who face poor prognoses after standard therapies through innovative next-generation cell therapies.

Allogene Therapeutics has previously highlighted efforts to drive innovation in CAR T therapy with a focus on broader patient access and new breakthroughs in cell treatment, as detailed in earlier company updates. Earlier this year, the company released interim ALPHA3 trial data showing early potential for allogeneic CAR T in LBCL treatment in a separate report. These developments reflect a continued push to improve outcomes for patients with difficult-to-treat blood cancers.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.